Genetic polymorphism of CYP2D6 and lung cancer risk in African-Americans and Caucasians in Los Angeles County

Carcinogenesis

Volumn 18, Issue 6, 1997, Pages 1203-1214

  London, S J ^a,b   Daly, A K ^c   Leathart, J B S ^c   Navidi, W C ^b,d   Carpenter, C C ^b   Idle, J R ^c,e  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d Department of Geology and Geological Engineering   (United States)

^e Inst Cancer Res and Molec Biol   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 ISOENZYME; DNA;

ADULT; AGED; ARTICLE; CANCER RISK; CAUCASIAN; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME POLYMORPHISM; FEMALE; GENE MUTATION; GENE NUMBER; HUMAN; HUMAN CELL; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NEGRO; PRIORITY JOURNAL; SMOKING; UNITED STATES;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AGED, 80 AND OVER; ALLELES; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP2D6; DNA, NEOPLASM; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENOTYPE; HUMANS; LOS ANGELES; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 0031408418     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/18.6.1203     Document Type: Article

References (48)

1. Daly, A.K., Cholerton, S., Gregory, W. and Idle, J.R. (1993) Metabolic polymorpisms. Pharmacol. Ther., 57, 129-160.
2. Crespi, C.L., Penman, B.W., Gelboin, H.V. and Gonzalez, F.J. (1991) A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6. Carcinogenesis. 7, 1197-1201.
3. McCracken, N.W., Cholerton, S. and Idle, J.R. (1992) Cotinine formation by cDNA-expressed human cytochromes P450. Med. Sci. Res., 20, 877-878.
4. Kato, S., Bowman, E.D., Harrington, A.M., Blomeke, B. and Shields, P.G. (1995) Human lung carcinogen-DNA adduct levels mediated by genetic polymorphisms in vivo. J. Natl Cancer Inst., 87, 902-907.
5. Ayesh, R., Idle, J.R., Ritchie, J.C., Crothers, M.J. and Hetzel, M.R. (1984) Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature, 312, 169-170.
6. Caporaso, N.E., Tucker, M.A., Hoover, R.N., et al. (1990). Lung cancer and the debrisoquine metabolic phenotype. J. Natl Cancer Inst., 82, 1264-1272.
7. Law, M.R., Hetzel, M.R. and Idle, J.R. (1989) Debrisoquine metabolism and genetic predisposition to lung cancer. Br. J. Cancer, 59, 686-687.
8. Roots, I., Drakoulis, N., Ploch, M., Heinemeyer, G., Loddenkemper, R., Minks, T., Nitz, M., Otte, F. and Koch, M. (1988) Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk. Klin-Wochenschr., 66 Suppl. 11, 87-97.
9. Benitez, J., Ladero, J.M., Jara, C., Carrillo, J.A., Cobaleda, J., Llerena, A., Vargas, E. and Munoz, J.J. (1991) Polymorphic oxidation of debrisoquine in lung cancer patients. Eur. J. Cancer, 27, 158-161.
10. Duche, J.P., Joanne, C., Barre, J, de Cremoux, H., Dalphin, J.C., Depierre, A., Brochard, P., Tillement, J.P. and Bechtel, P. (1991) Lack of a relationship between the polymorphism of debrisoquine oxidation and lung cancer. Clin. Pharmacol., 31, 533-536.
11. Shaw, G.L., Falk, R.T., Deslauriers, J., Frame, J.N., Nesbitt, J.C., Pass, H.I., Issaq, H.J., Hoover, R.N. and Tucker, M.A. (1995) Debrisoquine metabolism and lung cancer risk. Cancer Epidemiol. Biomarkers Prev., 4, 41-48.
12. Horsmans, Y., Desager, J.P. and Harvengt, C. (1991) Is there a link between debrisoquine oxidation phenotype and lung cancer susceptibility. Biomed. Pharmacother., 45, 359-362.
13. Speirs, C.J., Murray, S., Davies, D.S., Biola Madadeje, A.F. and Boobis, A.R. (1990) Debrisoquine oxidation phenotype and susceptibility to lung cancer. Br. J. Clin. Pharmacol., 29, 101-109.
14. Caporaso, N., Hayes, R.B., Dosemeci, M., Hoover, R., Ayesh, R., Hetzel, M. and Idle, J. (1989) Lung cancer risk, occupational exposure, and the debrisoquine metabolic phenotype. Cancer Res., 49, 3675-3679.
15. Bouchardy, C., Behamou, S. and Dayer, P. (1996) The effect of tobacco on lung cancer risk depends on CYP2D6 activity. Cancer Res., 56, 251-253.
16. Heim, M. and Meyer, U.A. (1990) Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet, 336, 529-532.
17. Gough, A.C., Miles, J.S., Spurr, N.K., Moss, J.E., Gaedigk, A., Eichelbaum, M. and Wolf, C.R. (1990) Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature, 347, 773-776.
18. Daly, A.K., Armstrong, M., Monkman, S.C., Idle, M.E. and Idle, J.R. (1991) The genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (P450IID6) phenotypes. Pharmacogenetics, 1, 33-41.
19. Hirvonen, A., Husgafvel-Pursiainen, K., Anttila, S., Karjalainen, A., Sorsa, M. and Vainio, H. (1992) Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer. Pharmacogenetics, 2, 259-263.
20. Wolf, C.R., Smith, C.A., Gough, A.C., et al. (1992) Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis, 13, 1035-1038.
21. Tefre, T., Daly, A.K., Armstrong, M., Leathart, J.B.S., Idle, J.R., Brogger, A. and Borresen, A.L. (1994) Genotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls. Pharmacogenetics, 4, 47-57.
22. Agundez, J.A., Martinez, C., Ladero, J.M., Ledesma, M.C., Ramos, J.M., Martin, R., Rodriguez, A., Jara, C. and Benitez, J. (1994) Debrisoquine oxidation genotype and susceptibility to lung cancer. Clin. Pharmacol. Ther., 55, 10-14.
23. Dolzan, V., Rudolf, Z. and Breskvar, K. (1995) Human CYP2D6 gene polymorphism in Slovene cancer patients and healthy controls. Carcinogenesis, 16, 2675-2678.
24. Stucker, I., Cosme, J., Laurent, P., Cenee, S., Beaune, P., Bignon, J., Depierre, A., Milleron, B. and Hemon, D. (1995) CYP2D6 genotype and lung cancer risk according to histologic type and tobacco exposure. Carcinogenesis, 16, 2759-2764.
25. Johansson, L., Lundqvist, E., Bertilsson, L., Dahl, M.-L., Sjoqvist, F. and Ingelman-Sundberg, M. (1993) Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl Acad. Sci. USA, 90, 11825-11829.
26. Agundez, J.A., Ledesma, M.C., Benitez, J., Ladero, J.M., Rodriguez Lescure, A., Diaz Rubio, E. and Diaz Rubio, M. (1995) CYP2D6 genes and risk of liver cancer. Lancet, 345, 830-831.
27. Evans, W.E., Relling, M.V., Rahman, A., McLeod, H.L., Scott, E.P. and Lin, J. (1993) Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. J. Clin. Invest., 91, 2150-2154.
28. Daly, A.K., Brockmöller, J., Broly, F., et al. (1996) Nomenclature for human CYP2D6 alleles. Pharmacogenetics, 6, 193-201.
29. Breslow, N.E. and Day, N.E. (1980) Statistical Methods in Cancer Research. I: The Analysis of Case-Control Studies. IARC Scientific Publications, Lyon, France.
30. London, S.J., Daly, A.K., Cooper, J., Navidi, W.C., Carpenter, C.L. and Idle, J.R. (1995) Polymorphism of glutathione S-transferase M1 and lung cancer risk among African-Americans and Caucasians in Los Angeles County, California. J. Natl Cancer Inst., 87, 1246-1253.
31. Hirji, K.F., Mehta, C.R. and Patel, N.R. (1987) Computing distributions for exact logistic regression. J. Am. Statist. Ass., 82, 1110-1117.
32. Daly, A.K., Steen, V.M., Fairbrother, K.S. and Idle, J.R. (1996) CYP2D6 multiallelism. Methods Enzymol., 272, 199-210.
33. Daly, A.K., Fairbrother, K.S., Andreassen, O.A., London, S.J., Idle, S.R. and Steen, V.M. (1996). Characterization and PCR-based detection of two different hydrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype. Pharmacogenetics, 6, 319-328.
34. Caporaso, N.E., DeBaun, M.R. and Rothman, N. (1995) Lung cancer and CYP2D6 (the debrisoquine polymorphism): sources of heterogeneity in the proposed association. Pharmacogenetics, 5, S129-S134.
35. Stram, D.O. (1996) Meta-analysis of published data using a linear mixed-effects model. Biometrics, 52, 108-115.
36. Hoffman, D., Brunnemann, K.D., Prokopczyk, B. and Djordjevic, M.V. (1994) Tobacco-specific N-nitrosamines and ARECA-derived N-nitrosamines: chemistry, biochemistry, carcinogenicity and relevance to humans. J. Toxicol. Environ. Hlth. 41, 1-52.
37. Devesa, S.S., Shaw, G.L. and Blot, W.J. (1991) Changing patterns of lung cancer incidence by histological type. Cancer Epidemiol. Biomarkers Prevent., 1, 29-34.
38. Benowitz, N.L., Peyton, J. and Perez Stable, E. (1996) CYP2D6 phenotype and metabolism of nicotine to cotinine. Pharmacogenetics, 6, 239-242.
39. Cholerton, S., Boustead, C., Taber, H., Arpanahi, A. and Idle, J.R. (1996) CYP2D6 genotypes in cigarette smokers and non-tobacco users. Pharmacogenetics, 6, 261-263.
40. London, S.J., Navidi, W.C., Daly, A.K. and Idle, J.R. (1996) Authors reply to correspondence re: S.J. London et al. Lung cancer risk in African-Americans in relation to a race-specific CYP1A1 polymorphism. Cancer Res., 56, 4276-4277.
41. Hennekens, C.H., Buring, J.E. (1987) Epidemiology in Medicine. Little Brown, Boston.
42. Fowler, F.J. (1988) Survey Research Methods. Sage Publications, Beverly Hills, CA.
43. Linden, J.V., Gregorio, D.I. and Kalish, R.I. (1988) An estimate of blood donor eligibility in the general population. Vox Sang., 54, 96-100.
44. Giovino, G.A., Schooley, M.W., Zhu, B., Chrismon, J.H., Tomar, S.L., Peddicord, J.P., Merritt, R.K., Husten, C.G. and Eriksen, M.P. Surveillance for selected tobacco-use behaviors - United States, 1900-1994. MMWR, 43, 1-43.
45. Brosen, K. (1990). Recent developments in hepatic drug oxidation, implications for clinical pharmacokinetics. Clin. Pharmacokinet., 18, 220-239.
46. Okada, T., Kawashima, K., Fukuchi, S., Minakuchi, T. and Nishimura, S. (1994) Association between a cytochrome P450 CYP1A1 genotype and incidence of lung cancer. Pharmacogenetics, 4, 333-340.
47. Dahl, M., Johannson, I., Palmertz, P. Ingelman-Sundberg, M. and Sjoqvist, F. (1992) Analysis of the CYP2D6 gene in relation to debrisoquine and desipramine hydroxylation in a Swedish population. Clin. Pharmacol. Ther., 51, 12-17.
48. Saxena, R., Shaw, G.L., Relling, M.V., Frame, J.N., Moir, D.T., Evans, W.E., Caporaso, N. and Weiffenbach, B. (1994) Identification of a new variant CYP2D6 single base pair deletion in exon 3 and its association with the poor metabolizer phenotype. Hum. Mol. Genet., 3, 923-926.